INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 204 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q1 2015. The put-call ratio across all filers is 1.01 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $160 | +240.4% | 8,580 | +100.0% | 0.00% | – |
| Q2 2023 | $47 | -19.0% | 4,290 | 0.0% | 0.00% | – |
| Q1 2023 | $58 | +9.4% | 4,290 | 0.0% | 0.00% | – |
| Q4 2022 | $53 | -99.9% | 4,290 | 0.0% | 0.00% | – |
| Q3 2022 | $60,000 | +1.7% | 4,290 | 0.0% | 0.00% | – |
| Q2 2022 | $59,000 | -15.7% | 4,290 | 0.0% | 0.00% | – |
| Q1 2022 | $70,000 | 0.0% | 4,290 | 0.0% | 0.00% | – |
| Q4 2021 | $70,000 | +9.4% | 4,290 | 0.0% | 0.00% | – |
| Q3 2021 | $64,000 | -25.6% | 4,290 | 0.0% | 0.00% | – |
| Q2 2021 | $86,000 | -13.1% | 4,290 | 0.0% | 0.00% | – |
| Q1 2021 | $99,000 | -6.6% | 4,290 | 0.0% | 0.00% | -100.0% |
| Q4 2020 | $106,000 | -40.4% | 4,290 | 0.0% | 0.00% | 0.0% |
| Q3 2020 | $178,000 | -13.6% | 4,290 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $206,000 | -23.7% | 4,290 | 0.0% | 0.00% | -50.0% |
| Q1 2020 | $270,000 | -38.6% | 4,290 | +20.9% | 0.00% | 0.0% |
| Q4 2019 | $440,000 | +87.2% | 3,548 | 0.0% | 0.00% | +100.0% |
| Q3 2019 | $235,000 | -16.7% | 3,548 | 0.0% | 0.00% | -50.0% |
| Q2 2019 | $282,000 | -29.0% | 3,548 | 0.0% | 0.00% | -33.3% |
| Q1 2019 | $397,000 | +10.9% | 3,548 | 0.0% | 0.00% | 0.0% |
| Q4 2018 | $358,000 | -20.1% | 3,548 | 0.0% | 0.00% | 0.0% |
| Q3 2018 | $448,000 | +50.3% | 3,548 | 0.0% | 0.00% | +50.0% |
| Q2 2018 | $298,000 | +14.6% | 3,548 | -16.0% | 0.00% | 0.0% |
| Q1 2018 | $260,000 | +5.3% | 4,226 | +0.0% | 0.00% | 0.0% |
| Q4 2017 | $247,000 | +3.3% | 4,224 | +2.7% | 0.00% | 0.0% |
| Q3 2017 | $239,000 | -52.0% | 4,111 | 0.0% | 0.00% | -50.0% |
| Q2 2017 | $498,000 | +8.3% | 4,111 | +1.1% | 0.00% | +33.3% |
| Q1 2017 | $460,000 | +3.8% | 4,068 | -0.2% | 0.00% | -25.0% |
| Q4 2016 | $443,000 | -34.0% | 4,075 | -0.0% | 0.00% | -20.0% |
| Q3 2016 | $671,000 | +15.5% | 4,077 | +0.0% | 0.01% | 0.0% |
| Q2 2016 | $581,000 | +11.3% | 4,075 | +0.3% | 0.01% | +25.0% |
| Q1 2016 | $522,000 | +6.3% | 4,061 | +23.5% | 0.00% | 0.0% |
| Q4 2015 | $491,000 | -9.9% | 3,288 | +0.2% | 0.00% | -20.0% |
| Q3 2015 | $545,000 | -31.4% | 3,283 | -0.2% | 0.01% | -16.7% |
| Q2 2015 | $794,000 | -12.3% | 3,289 | +2.5% | 0.01% | -14.3% |
| Q1 2015 | $905,000 | +138.2% | 3,209 | +31.7% | 0.01% | +133.3% |
| Q4 2014 | $380,000 | -34.3% | 2,436 | -0.2% | 0.00% | -40.0% |
| Q3 2014 | $578,000 | +495.9% | 2,442 | +497.1% | 0.01% | +400.0% |
| Q2 2014 | $97,000 | – | 409 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 635,300 | $53,308,000 | 10.69% |
| Senvest Management, LLC | 976,127 | $81,907,000 | 5.65% |
| Melqart Asset Management (UK) Ltd | 390,600 | $32,775,000 | 2.80% |
| Asymmetry Capital Management, L.P. | 25,918 | $2,175,000 | 2.14% |
| Elk Creek Partners, LLC | 386,397 | $32,423,000 | 1.78% |
| BB BIOTECH AG | 545,719 | $45,791,000 | 1.32% |
| ALTRINSIC GLOBAL ADVISORS LLC | 383,166 | $32,151,000 | 1.27% |
| DLD Asset Management, LP | 129,000 | $10,824,000 | 0.82% |
| Opus Point Partners Management, LLC | 3,998 | $335,000 | 0.73% |
| Virtus ETF Advisers LLC | 8,970 | $753,000 | 0.67% |